HR Perspectives by John Dawber: “Adoption Improves Dramatically when AI Becomes Tangible in Daily Work Rather than an Abstract Future Concept”

Why It Matters

Embedding AI in routine tasks drives faster adoption and operational efficiency in highly regulated pharma environments, while focusing on potential over static skills strengthens the talent pipeline essential for innovation.

Key Takeaways

• AI adoption spikes when embedded in daily tasks, not just theory
• Novo Nordisk prioritizes learning agility over current skill sets
• Representation without decision‑making power remains a core diversity challenge
• Balanced internal development and external hiring fuels senior leadership pipeline
• Human‑in‑the‑loop approach mitigates expert resistance to AI tools

Pulse Analysis

In the pharmaceutical sector, the promise of artificial intelligence often collides with the reality of stringent regulations and deeply entrenched scientific processes. Novo Nordisk’s experience shows that AI gains traction when it moves from theoretical discussion to concrete, day‑to‑day applications such as literature reviews, safety surveillance, and documentation. This shift reduces perceived risk, eases expert resistance, and demonstrates measurable efficiency gains, setting a benchmark for other regulated industries seeking to modernise without compromising compliance.

Talent strategy is another focal point. The company’s emphasis on learning agility—curiosity, adaptability, and cross‑disciplinary collaboration—reflects a broader industry trend of hiring for future potential rather than current skill sets. By coupling internal leadership pipelines with selective external hires, Novo Nordisk balances deep institutional knowledge with fresh digital expertise. Crucially, the firm highlights that mere representation does not equal influence; true inclusion requires visible decision‑making power, a lesson that resonates across global HR practices.

Finally, Novo Nordisk’s human‑in‑the‑loop approach to AI underscores a pragmatic path forward. Rather than replacing seasoned experts, AI tools augment judgment, preserving the nuanced decision‑making essential in drug development and patient safety. This model mitigates cultural pushback, aligns with regulatory expectations, and positions the company to scale AI responsibly. As more pharma firms grapple with similar challenges, the blend of tangible AI deployment, agile talent development, and inclusive leadership will likely define the next wave of industry transformation.